fda warning letters compounded semaglutide tirzepatide september 2025 From Crackdown to Collaboration: and the Hims-Novo Nordisk Deal Signal a New Era for GLP-1 Drugs Are Compounded GLP-1s Going Away?

The Phase 2 data showing 24.2% body weight loss in 48 weeks through a novel triple-agonist mechanism is unprecedented

Gut symptoms can increase during those weeks

Glucagon Receptor Engagement Energy Expenditure and Hepatic Metabolism Although GLP3 exhibits lower potency at glucagon receptors compared to native glucagon, this component of its triagonist mechanism appears critical for its metabolic effects[8]: Increased energy expenditure through thermogenic activation Enhanced hepatic fatty acid oxidation and reduced hepatic steatosis Modulation of hepatic glucose production during fasted states Promotion of lipolysis in adipose tissue Potential effects on lean mass preservation through metabolic adaptations In vitro studies demonstrated that GLP3 achieves efficacy similar to natural glucagon in stimulating glucose production in hepatocytes, while in adipocytes it surpasses native GIP in inducing lipolysis[9]

JCI Insight 2020, 5(17)

Either copper peptide alone works if availability or tolerance is a constraint

No membership fees, state licensing in all 50 states, and transparent pricing eliminate hidden financial surprises